Pharmaceutical Industry Report - Clinical Report, Drug R&D Report, Pharmaceutical Information

Global Drug R&D Express (Jan 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 68 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (Dec 2023)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 104 drugs. Among them, 2 first-to-market drugs and 5 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (Nov 2023)

This report compiles and summarizes the basic information of all the first-to-market and special-review medicines globally in November, totaling 104. From these, 5 first-to-market medicines and 5 special-review medicines have been meticulously selected. The report provides a detailed interpretation of these medicines, covering multiple aspects such as their basic information, development status, technological barriers, mechanisms of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (Oct 2023)

The data in this report has been sourced from Patsnap Synapse, a novel AI-powered database that offers a search and association platform with intuitive interfaces, curated content, and integrated access to massive information sources that connect company data, diseases, targets, and clinical studies to biological and chemical entities. Based on data from the Synapse database, we recently published Global Innovative Drug Report, which offers a comprehensive overview of the latest advancements in the pharmaceutical industry and analysis of each selected drug, examining their snapshot, R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors. The report consists of four parts: >>1.First Approved Drugs in October 2023; >>2. New Drug Analysis; >>3.Global Drugs under Expedited Review Pathway in October 2023; >>4. Analysis of Selected ERP Drugs.

Read →

Global Drug R&D Express (Sep. 2023)

Based on data from the Synapse database, we recently published Global Innovative Drug Report, which offers a comprehensive overview of the latest advancements in the pharmaceutical industry and analysis of each selected drug, examining their snapshot, R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors. The report consists of four parts:1.First Approved Drugs in September; 2. New Drug Analysis; 3.Global Drugs under Expedited Review Pathway in September; 4. Analysis of Selected ERP Drugs

Read →

Global Drug R&D Express (Aug. 2023)

Based on data from the Synapse database, we recently published Global Innovative Drug Report, which offers a comprehensive overview of the latest advancements in the pharmaceutical industry and analysis of each selected drug, examining their snapshot, R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors. The report consists of four parts:1.First Approved Drugs in August; 2. New Drug Analysis; 3.Global Drugs under Expedited Review Pathway in August; 4. Analysis of Selected ERP Drugs

Read →

Global Drug R&D Express (Jul. 2023)

Based on data from the PatSnap Synapse database, we recently published Global Innovative Drug Report, which offers a comprehensive overview of the latest advancements in the pharmaceutical industry and analysis of each selected drug, examining their snapshot, R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors. The report consists of four parts:1.First Approved Drugs in July; 2. New Drug Analysis; 3. Global Drugs under Expedited Review Pathway in July; 4. Analysis of Selected ERP Drugs

Read →

Global Drug R&D Express (Jun. 2023)

Based on the latest data from PatSnap Synapse, we has released the "Global Drug R&D Express (May 2023)". The report includes a total of 75 drugs consisting of: ◉ 14 drugs first approved globally: 7Small molecule drug (SMD), 1 Monoclonal antibody(mAb), 1 Enzyme, 1 CAR-T, 1 Fc fragment, 1 Cell therapy, 1 Adeno-associated virus gene therapy 1 traditional Chinese medicine.◉ 58 drugs under Expedited Review pathways worldwide: 32 Orphan Drug designation, 12 Fast Track designation, 9 Priority review, 4 Breakthrough Therapy designation, 2 Accelerated Approval, 1 Qualified Infectious Disease Product, 1 PRIME. The report also highlights 5 first approved drugs and 6 Expedited Review Pathway drugs providing a detailed interpretation of the drugs from multiple aspects such as basic information, R&D status, technical barriers, mechanisms of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (May 2023)

Based on the latest data from PatSnap Synapse, Zhihuiya has released the "Global Drug R&D Express (May 2023)". The report includes a total of 75 drugs consisting of: ◉ 18 drugs first approved globally: 5 Small molecule drug (SMD), 4 Monoclonal antibody(mAb), 2 Prophylactic vaccine, 2 Allergen extract, 1 Blood components, 1 Gene therapy, 1 Bispecific antibody, 1 Enzyme, 1 Fusion protein. ◉ 57 drugs under Expedited Review pathways worldwide: 32 Orphan Drug designation, 12 Fast Track designation, 5 Priority review, 4 Breakthrough Therapy designation, 2 Regenerative Medicine Advanced Therapy, 1 Innovative Licensing and Access Pathway (ILAP), 1 Accelerated Approval. The report also highlights: ◼ 5 first approved drugs: Benegrastim, Fezolinetant, Zebituzumab, Perfluorohexyloctane, Beremagene geperpavec ◼ 5 Expedited Review Pathway drugs: Spesolimab, Mefatinib, Resiniferatoxin, Nirsevimab, Fruquintinib, providing a detailed interpretation of the drugs from multiple aspects such as basic information, R&D status, technical barriers, mechanisms of action, clinical trials, and competitive landscape.

Read →